Market Place
Sourcing Support
Sandoz`s Biologic Enzeevu Receives Suppl Approval in US
10 Feb 2025 //
FDA
EYLEA HD 8 mg Ph 3 Results for Macular Edema Retinal Vein
08 Feb 2025 //
GLOBENEWSWIRE
EYLEA HD® 8 mg Shows Durable Vision Gains in Wet AMD 3-Year Data
08 Feb 2025 //
GLOBENEWSWIRE
Lotus Pharma Partners for Eylea® Biosimilar FYB203 in APAC Region
05 Feb 2025 //
PHARMAWEB
Teva To Commercialize Formycon’s Eylea Biosimilar In Europe, Israel
13 Jan 2025 //
GLOBENEWSWIRE
Regeneron to expand high-dose Eylea`s label after Ph 3 win
18 Dec 2024 //
BIOSPACE
EC grants approval to Sandoz’s biosimilar to treat retinal diseases
16 Nov 2024 //
FINANCIALXPRESS
Sandoz Receives EC Approval for Afqlir® Biosimilar
15 Nov 2024 //
GLOBENEWSWIRE
Eylea 8 mg Efficacy In Diabetic Macular Edema Confirmed At 3 Years
19 Oct 2024 //
INDPHARMAPOST
EYLEA HD® Injection Shows Gains In Diabetic Macular Edema.
18 Oct 2024 //
GLOBENEWSWIRE
Regeneron`s Biologic Eylea HD (Aflibercept) Receives Suppl Approval in US
10 Oct 2024 //
FDA
Regeneron Pharma`s Biologic Eylea Receives Suppl Approval in US
10 Oct 2024 //
FDA
Samsung Bioepis and Biogen Receive Positive CHMP
20 Sep 2024 //
GLOBENEWSWIRE
EYLEA HD Data At EURETINA Shows Long-term Durability And Safety
11 Sep 2024 //
GLOBENEWSWIRE
EMA Accepts Marketing Application For AVT06, Biosimilar To Eylea (Aflibercept)
15 Aug 2024 //
GLOBENEWSWIRE
Alvotech Reports Record Revenues And Adjusted EBITDA For Q2 And H1 2024
15 Aug 2024 //
GLOBENEWSWIRE
Sandoz Gets FDA Approval For Enzeevu, Boosting US Biosimilar Position
12 Aug 2024 //
GLOBENEWSWIRE
European Commission Approves Roche`s Vabysmo For Retinal Vein Occlusion
30 Jul 2024 //
GLOBENEWSWIRE
Altos Biologics Files for Approval of Aflibercept Biosimilar
01 Jul 2024 //
PR NEWSWIRE
Formycon`s Biologic Ahzantive (aflibercept-mrbb) Receives Approval in US
28 Jun 2024 //
FDA
Alvotech and STADA add to strategic alliance through denosumab partnership
12 Jun 2024 //
PRESS RELEASE
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 at Summit
07 Jun 2024 //
GLOBENEWSWIRE
Enforcement Report - Week of June 5, 2024
05 Jun 2024 //
FDA
Rezolute’s oral Eylea rival hits phase 2 goal, sending stock up
22 May 2024 //
FIERCE BIOTECH
Biocon Gets US Approval For Biosimilar Aflibercept Yesafili
21 May 2024 //
PR NEWSWIRE
Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili
21 May 2024 //
INDINPHARMAPOST
US FDA approves two biosimilars for blockbuster eye drug Eylea
21 May 2024 //
REUTERS
Biocon Biologics’ Yesafili (aflibercept-jbvf) Receives Approval In U.S
20 May 2024 //
FDA
Bayer de-emphasizes the impact of Roche`s Vabysmo on Eylea sales
15 May 2024 //
FIERCE PHARMA
MS Pharma becomes Partner for the Commercialization of FYB203, Formycon
14 May 2024 //
PHARMIWEB
Roche’s soaring Vabysmo sales challenge Regeneron’s Eylea
10 May 2024 //
FIERCE PHARMA
Dupixent COPD delay possible, Eylea down 2%, Regeneron says
03 May 2024 //
FIERCE PHARMA
EYLEA® HD Data in Retinal Diseases at ARVO 2024
29 Apr 2024 //
GLOBENEWSWIRE
US FDA warns of harmful reactions to fake Botox injections
17 Apr 2024 //
REUTERS
US accuses Regeneron of fraudulent price reporting for eye drug
12 Apr 2024 //
REUTERS
Bayer Pharmaceuticals advances next generation of blockbuster medicines
21 Mar 2024 //
PRESS RELEASE
Aflibercept 8 mg clinical study data now published in The Lancet
08 Mar 2024 //
PRESS RELEASE
EYLEA Injection 8 mg Pivotal Data in wAMD and DME Published in The Lancet
08 Mar 2024 //
GLOBENEWSWIRE
Regeneron touts `favorable` physician reports on Eylea HD
03 Feb 2024 //
FIERCE PHARMA
New Eylea™ 8 mg approved in Japan
18 Jan 2024 //
PRESS RELEASE
New Eylea™ 8 mg approved in EU
08 Jan 2024 //
PRESS RELEASE
Alvotech Study Results Demonstrate Therapeutic Equivalence between AVT06
03 Jan 2024 //
GLOBENEWSWIRE
Regeneron Gains After Eye-Drug Patent Victory Over Viatris
28 Dec 2023 //
BLOOMBERG
Regeneron`s Biologic Eylea (aflibercept) Receives Approval in the U.S.
14 Dec 2023 //
FDA
Sanofi`s Biologic Zaltrap (ziv-aflibercept) Receives Approval in the U.S.
13 Dec 2023 //
FDA
Biocon Biologics receives MHRA Approval for Biosimilar Aflibercept ‘Yesafili’
14 Nov 2023 //
INDIAN PHARMA POST
Bayer’s aflibercept 8 mg recommended for approval in EU
11 Nov 2023 //
PRESS RELEASE
With high-dose Eylea launch, Regeneron eyes battle with Roche
02 Nov 2023 //
FIERCE PHARMA
EYLEA Injection 8 mg Data Presentations at AAO Reinforce Efficacy
01 Nov 2023 //
GLOBENEWSWIRE
EYLEA Injection 8 mg Results from Pivotal PULSAR Trial Presented
05 Oct 2023 //
GLOBENEWSWIRE
After wet AMD trial, Unity gathers around diabetic macular edema
27 Sep 2023 //
FIERCE BIOTECH
Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data
26 Sep 2023 //
GLOBENEWSWIRE
Regeneron`s Biologic Eylea (Aflibercept) Receives Approval in the U.S.
18 Aug 2023 //
FDA
Novartis` Eylea biosimilar adds to pressure on Regeneron`s star
16 Aug 2023 //
FIERCE PHARMA
Regeneron expects FDA decision on higher-dose Eylea this year
04 Aug 2023 //
REUTERS
Aflibercept 8 Mg Two-Year Results From Pivotal Photon Trial Presented At Asrs
29 Jul 2023 //
PRESS RELEASE
Biocon Announces Positive CHMP Opinion for YESAFILI, Biosimilar Aflibercept
25 Jul 2023 //
PR NEWSWIRE
